Citigroup’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-42,800
Closed -$7.7M 7797
2017
Q3
$7.7M Buy
42,800
+400
+0.9% +$55.7K 0.01% 1412
2017
Q2
$4.39M Buy
42,400
+15,600
+58% +$1.27M ﹤0.01% 1809
2017
Q1
$2.1M Sell
26,800
-200
-0.7% -$12.4K ﹤0.01% 2431
2016
Q4
$1.21M Buy
27,000
+1,600
+6% +$78.5K ﹤0.01% 3482
2016
Q3
$1.42M Buy
25,400
+8,300
+49% +$462K ﹤0.01% 2855
2016
Q2
$855K Sell
17,100
-600
-3% -$29.5K ﹤0.01% 3113
2016
Q1
$813K Sell
17,700
-9,000
-34% -$436K ﹤0.01% 3581
2015
Q4
$1.65M Sell
26,700
-10,200
-28% -$718K ﹤0.01% 2637
2015
Q3
$2.06M Buy
36,900
+6,200
+20% +$390K ﹤0.01% 2422
2015
Q2
$1.87M Buy
30,700
+25,100
+448% +$1.43M ﹤0.01% 2580
2015
Q1
$323K Buy
+5,600
New +$375K ﹤0.01% 4124

Citigroup's KITE Position: Q4 2017 in Review

Citigroup sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 356,484 shares — an estimated $64.1M sold.

Citigroup first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $64.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Citigroup reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Citigroup sold 356,484 Kite Pharma, Inc. shares in Q4 2017, an estimated $64.1M.
  • Citigroup first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • Citigroup's Kite Pharma, Inc. position peaked at $64.1M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Citigroup's 13F filing for Q4 2017, filed 12 Feb 2018.